Per-Uno Malmström
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Per-Uno Malmström has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Abolfazl Hosseini-Aliabad
Center for Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden
1 shared publication- Amir Sherif
Department of Diagnostics and Intervention, Urology and Andrology, Umeå University, Umeå, Sweden
1 shared publication Firas Aljabery
Department of Urology, Linköping University Hospital, Linköping, Sweden
1 shared publicationFredrik Liedberg
Department of Urology, Skåne University Hospital, Malmö, Sweden
1 shared publicationGårdmark Truls
Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden
1 shared publicationStaffan Jahnson
Department of Urology, Linköping University Hospital, Linköping, Sweden
1 shared publication
Latest Publications
- Open Access
- 21 November 2023
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 58 (1) , 109-114
Abandoning testing for asymptomatic microscopic haematuria in Sweden – a long-term follow-up
Objectives: To test the hypothesis that the Swedish national policy of abandoning testing for asymptomatic microscopic haematuria (AMH) introduced in 1999 did not adversely affect the prognosis of patients with urinary bladder cancer. Specific aims were to investigate possible effects on (1) Diagnostic delay as represented by stage distribution at diagnosis, (2) Survival and mortality trends, also in comparison to other countries and (3) National health care costs. Material and methods: The design was an observational study using open sources on patients included in the Swedish National Bladder Cancer Registry 1997–2016. Outcome measures were: Changes in initial tumour presentation during 5 years after the change and long-term relative survival and mortality in comparison to the other Nordic countries. Costs related to investigations were estimated based on the national price lists. Results: The proportion of patients diagnosed with muscle-invasive bladder cancer decreased following the policy change. The long-term relative 5-year survival increased during the study period. Mortality has remained constant during the period. In comparison to the other Nordic countries, Sweden remains among those with the best outcome despite a more restrictive approach. Cost savings because of the policy change were estimated to be substantial. Conclusions: Based on open-source registry data, the new restrictive policy was not found to adversely affect the survival of patients with urinary bladder cancer in Sweden. These observations argue against a major negative impact of abandoning further work-up for patients with AMH and may be of use for other countries when revising guidelines. The reduced number of patients undergoing investigation may allow for increased focus and be a relief both for caregivers and the health budget.
- 21 November 2023
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 58 (1) , 109-114
Open AccessAbandoning testing for asymptomatic microscopic haematuria in Sweden – a long-term follow-up
Objectives: To test the hypothesis that the Swedish national policy of abandoning testing for asymptomatic microscopic haematuria (AMH) introduced in 1999 did not adversely affect the prognosis of patients with urinary bladder cancer. Specific aims were to investigate possible effects on (1) Diagnostic delay as represented by stage distribution at diagnosis, (2) Survival and mortality trends, also in comparison to other countries and (3) National health care costs. Material and methods: The design was an observational study using open sources on patients included in the Swedish National Bladder Cancer Registry 1997–2016. Outcome measures were: Changes in initial tumour presentation during 5 years after the change and long-term relative survival and mortality in comparison to the other Nordic countries. Costs related to investigations were estimated based on the national price lists. Results: The proportion of patients diagnosed with muscle-invasive bladder cancer decreased following the policy change. The long-term relative 5-year survival increased during the study period. Mortality has remained constant during the period. In comparison to the other Nordic countries, Sweden remains among those with the best outcome despite a more restrictive approach. Cost savings because of the policy change were estimated to be substantial. Conclusions: Based on open-source registry data, the new restrictive policy was not found to adversely affect the survival of patients with urinary bladder cancer in Sweden. These observations argue against a major negative impact of abandoning further work-up for patients with AMH and may be of use for other countries when revising guidelines. The reduced number of patients undergoing investigation may allow for increased focus and be a relief both for caregivers and the health budget.
- 2 July 2019
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 53 (4) , 193-199
Incidence, survival and mortality trends of bladder cancer in Sweden 1997–2016
Objective: To evaluate trends in bladder cancer incidence, survival and mortality in Sweden from 1997–2016. Patients and methods: The Swedish National Registry of Urinary Bladder Cancer is a nation-wide quality register that started in 1997. It includes information on initial tumor characteristics and treatment; 41,097 new cases were registered up to 2016. Patients were stratified into four time periods. Deaths were monitored through the national death register. Overall and relative survival in time periods were studied with respect to differences in stage, age and gender. Results: The number of new cases increased by 38% for men and 39% for women from 1997 to 2016. The corresponding age-standardized incidence per 100,000 was less dramatic, with increases of 6% and 21%, respectively, and the increase was most evident in the oldest age group. The survival rate was stable until 2012, but thereafter a significant improvement occurred. The survival trends in stage-groups show that this improvement is found in all categories as well as irrespective of age and gender. The mortality rate during this period was stable for women, but showed a slight decrease for men. The main limitation of this study is the use of administrative data for defining some of the endpoints. Conclusion: The most recent Swedish bladder cancer statistics show an increased incidence, improved survival, but stable mortality.
- 2 July 2019
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 53 (4) , 193-199
Incidence, survival and mortality trends of bladder cancer in Sweden 1997–2016
Objective: To evaluate trends in bladder cancer incidence, survival and mortality in Sweden from 1997–2016. Patients and methods: The Swedish National Registry of Urinary Bladder Cancer is a nation-wide quality register that started in 1997. It includes information on initial tumor characteristics and treatment; 41,097 new cases were registered up to 2016. Patients were stratified into four time periods. Deaths were monitored through the national death register. Overall and relative survival in time periods were studied with respect to differences in stage, age and gender. Results: The number of new cases increased by 38% for men and 39% for women from 1997 to 2016. The corresponding age-standardized incidence per 100,000 was less dramatic, with increases of 6% and 21%, respectively, and the increase was most evident in the oldest age group. The survival rate was stable until 2012, but thereafter a significant improvement occurred. The survival trends in stage-groups show that this improvement is found in all categories as well as irrespective of age and gender. The mortality rate during this period was stable for women, but showed a slight decrease for men. The main limitation of this study is the use of administrative data for defining some of the endpoints. Conclusion: The most recent Swedish bladder cancer statistics show an increased incidence, improved survival, but stable mortality.
- 1 August 2017
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 35 (8) , 532.e1-532.e6
Validation of the ezrin, CK20, and Ki-67 as potential predictive markers for BCG instillation therapy of non–muscle-invasive bladder cancer
- 1 August 2017
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 35 (8) , 532.e1-532.e6
Validation of the ezrin, CK20, and Ki-67 as potential predictive markers for BCG instillation therapy of non–muscle-invasive bladder cancer